Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
SLDB Total Current Liabilities
All obligations due within one year.
Solid Biosciences Inc.NASDAQ: SLDB
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 5.2% from a year ago
Total current liabilities stood at $30.28M at the end of Q1 FY2026, up 5.2% from a year earlier and down 9.5% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.
Context
- Total current liabilities amounted to 7.2% of total assets at the end of Q1 FY2026, down 1.2 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +5.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 33.47M USD
- Year-over-year change
- +10.6%
- 4-year CAGR
- +9.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.47M | +10.6% |
| FY2024 | 2024-12-31 | 30.26M | +108.4% |
| FY2023 | 2023-12-31 | 14.52M | -35.5% |
| FY2022 | 2022-12-31 | 22.51M | -4.6% |
| FY2021 | 2021-12-31 | 23.6M | — |
Total Current Liabilities vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's Mar 2026 total current liabilities of $30.28M is the 8th highest of the 10 companies compared; the peer median is $78.03M.
- Its year-over-year change of +5.2% is the 8th highest of 10, against a peer median of +50.6%.
- Total current liabilities amounts to 7.2% of total assets for SLDB, versus a peer median of 8.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $771.07M | +22.8% | +33.6% | 23.7% | |
| Mar 2026 | $499.16M | -17.6% | +20.9% | 15.7% | |
| Mar 2026 | $176.13M | +236.3% | +14.3% | 72.0% | |
| Sep 2026 | $144.11M | +565.7% | +18.2% | 8.1% | |
| Jun 2026 | $78.03M | +88.1% | +21.7% | 7.8% | |
| Mar 2026 | $43.4M | +61.4% | +40.9% | 8.5% | |
| Mar 2026 | $33.64M | +50.6% | +15.0% | 10.3% | |
| Mar 2026 | $30.28M | +5.2% | +14.1% | 7.2% | |
| Mar 2026 | $18.87M | +33.9% | +35.1% | 7.2% | |
| Mar 2026 | $8.96M | -56.1% | -12.4% | 5.7% | |
| Peer median (excluding SLDB) | $78.03M | +50.6% | +20.9% | 8.5% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 119.14M | 155.38M | 74.02M | 80.24M | 59.9M |
| Short-term Investments | 88.64M | 58.34M | 49.63M | 68.69M | 127.95M |
| Net Receivables | 110K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.71M | 3M | 2.11M | 1.65M | 17.61M |
| Total Current Assets | 222.61M | 219.64M | 129.73M | 157.3M | 205.46M |
| Property, Plant & Equipment (Net) | 7.6M | 38.61M | 33.16M | 29.04M | 26.09M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.16M | 2.01M | 2.04M | 2.32M | 991K |
| Total Non-current Assets | 9.77M | 40.61M | 35.21M | 31.36M | 27.08M |
| Total Assets | 232.38M | 260.25M | 164.94M | 188.66M | 232.54M |
| Account Payables | 4.46M | 3.24M | 2.03M | 4.24M | 3.22M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.1M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 8.08M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.12M | 8.38M | 5.95M | 9.37M | 28.15M |
| Total Current Liabilities | 23.6M | 22.51M | 14.52M | 30.26M | 33.47M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 96K | 0 | 0 | 0 |
| Total Non-current Liabilities | 568K | 26.08M | 23.94M | 21.16M | 19.06M |
| Total Liabilities | 24.17M | 48.59M | 38.46M | 51.42M | 52.53M |
| Common Stock | 7K | 20K | 20K | 40K | 79K |
| Retained Earnings | (476.76M) | (562.74M) | (658.75M) | (783.45M) | (957.78M) |
| Accumulated OCI | (45K) | (68K) | 15K | 47K | 52K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 208.21M | 211.67M | 126.48M | 137.25M | 180.01M |
| Total Debt | 2.06M | 28.55M | 26.27M | 24.18M | 21.16M |
| Net Debt | (117.07M) | (126.84M) | (47.75M) | (56.06M) | (38.74M) |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.